Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study.

Helen W WongVivian H NguyenTimothy Y MokFang NiuMerta CushingMichael LamStephanie L HoLisa Y LawAshraf R AzizRita L Hui

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)

We demonstrated that rituximab-abbs was noninferior to rituximab in both effectiveness and safety among patients receiving R-CHOP for DLBCL in this study. Long-term follow-up would be needed to confirm these results.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
type diabetes
metabolic syndrome
adipose tissue
hodgkin lymphoma
insulin resistance